[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parturients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parturients":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642691","phase-4-intranasal-esketamine-dexmedetomidine-combination-and-postpartum-depression-100642691",false,"NCT07639099","Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","Impact of Intranasal Esketamine-dexmedetomidine Combination on Postpartum Depression in Parturients With Prenatal Depressive Symptoms: a Randomized, Double-blind, and Placebo-controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years who are preparing for childbirth;\n* Positive prenatal depression screening, defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥5.\n\nExclusion Criteria:\n\n* History of schizophrenia or existence of communication barriers;\n* Severe obstetric complications, including severe preeclampsia, placenta accreta, HELLP syndrome, placenta previa, placental abruption, or ASA physical status classification \\>III;\n* Contraindications to ketamine\u002Fesketamine, including refractory hypertension, severe cardiovascular disease (NYHA class ≥III), or hyperthyroidism;\n* Contraindications to dexmedetomidine, including severe bradycardia (heart rate \\\u003C50 bpm), or second-degree or higher atrioventricular block;\n* Unsuitable for intranasal administration due to nasal cavity diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause);\n* Refusal to participate in this study or concurrent participation in another clinical trial.","FEMALE","18 Years",{"count":19,"type":20},164,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.",[26,27,28,29,30,31],"Parturients","Depressive Symptoms","Esketamine","Dexmedetomidine","Intranasal Administration","Postpartum Depression",[26,33,28,29,34,35],"Prenatal depressive symptoms","Intranasal administration","Postpartum depression","NOT_YET_RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":20},"2026-06",{"date":44,"type":20},"2029-12",{"name":46,"class":47},"Peking University First Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100626633","maternal-satisfaction-after-spinal-anesthesia-for-cesarean-delivery-100626633","NCT07438171","Maternal Satisfaction After Spinal Anesthesia for Cesarean Delivery","Maternal Satisfaction Following Different Spinal Anesthesia Regimens for Elective Cesarean Delivery: a Prospective Observational Study","Inclusion Criteria: Parturients for elective cesarean delivery, ASA, status II and III, age between 18 and 45 years, singleton pregnancy, able to provide inform consent. -\n\nExclusion Criteria: Refuse to participate in the study, spinal anesthesia refused, known drug allergies to drugs included in the study, multiple pregnancy, preterm gestation, skin lesion at the beck, severe maternal comorbidities, chronic opioid use and chronic pain. -","45 Years",{"count":58,"type":20},200,"OBSERVATIONAL","The goal of this observational study is to evaluate the impact of four different spinal anesthesia regimens on maternal satisfaction following cesarean delivery.\n\nThe main questions this study aims to answer are:\n\n* Primary outcome: Patient satisfaction with the provided analgesia during the first 24 hours postoperatively.\n* Secondary outcome: The need for rescue analgesics. Participants will complete a specially designed questionnaire 24 hours after cesarean delivery.",[26,62],"Elective Cesarean Delivery",[64,65,66,67],"Maternal satisfaction","Spinal anesthesia","cesarean delivery","postcesarean analgesia","2026-02-22",{"date":70,"type":40},"2026-02-27",{"date":72,"type":20},"2026-03-02",{"date":74,"type":20},"2026-09-01",{"name":76,"class":47},"University of Novi Sad"]